Trial Profile
An open label study to evaluate long-term safety and efficacy of canakinumab in patients with active, recurrent or chronic TNF receptor-associated periodic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2016
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Familial autosomal dominant periodic fever
- Focus Therapeutic Use
- 03 Feb 2016 New trial record